# Sermorelin FAQ: Twenty-Five Questions Answered from the Research Literature > Sermorelin FAQ — twenty-five most-asked questions about Sermorelin answered with citations from the published clinical research literature. Mechanism, pharmacokinetics, comparisons, regulatory status. ## Definitional Sermorelin is the synthetic 29-amino-acid GHRH (1-29) fragment, and several of the most common questions are simply asking what it is and how it works. ### What is Sermorelin? Sermorelin is a synthetic 29-amino-acid peptide corresponding to the bioactive N-terminal fragment of growth hormone-releasing hormone (GHRH 1-29), studied as a stimulator of endogenous growth hormone secretion [1][7]. The molecule has a molecular weight of 3,357.9 Da and the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. ### What does Sermorelin do to the body? Binds the GHRH receptor on anterior pituitary somatotrophs, stimulating pulsatile release of endogenous human growth hormone, which in turn drives hepatic IGF-1 production [1][7]. The effect operates within the body's preserved negative-feedback architecture from somatostatin and circulating IGF-1. ### How does Sermorelin work? Engages pituitary GHRH receptors to amplify the body's natural GH pulse rather than supplying exogenous GH; the effect is downstream-physiologic, not replacement [7]. Continuous (non-pulsatile) administration produces tachyphylaxis at the somatotroph, which is why published trials use intermittent bedtime dosing [18]. ### What is Sermorelin used for in research? Historically studied as a diagnostic for pituitary GH reserve (1 mcg/kg IV provocative test) and as a treatment for pediatric idiopathic GH deficiency (30 mcg/kg SC at bedtime) [3][6]; later research explores adult-onset GH decline [9][10][21]. Modern reviews place Sermorelin primarily in the GH-secretagogue pharmacology class [12]. ## Safety and Efficacy ### Is Sermorelin safe? Generally well tolerated in clinical trials; the most common adverse events were transient injection-site reactions in the pediatric international multi-site study group cohort and across the adult research literature [3][9]. Serum cortisol, prolactin, and thyroid-axis disturbances are not characteristic. Long-term safety data in adults remains limited because long-duration adult trials are sparse. ### Does Sermorelin work? Clinical trials report measurable increases in serum GH and IGF-1 versus baseline; magnitude and clinical relevance vary by population studied [3][9][10]. The strongest efficacy data is in pediatric idiopathic GHD, where height-velocity acceleration was clinically meaningful at 30 mcg/kg subcutaneously nightly [3]. ### What are the downsides of Sermorelin? Short plasma half-life of approximately 11-12 minutes requires frequent dosing [5]; effect is blunted or absent in patients with intrinsic pituitary failure because there are no somatotrophs to stimulate [8]; tachyphylaxis is observed with continuous (non-pulsatile) administration, requiring intermittent bedtime dosing [18]. ### Who should not use Sermorelin? Active malignancy, intracranial lesions, and known hypersensitivity are exclusion criteria in published trials. The proliferative-axis concern with active malignancy applies broadly to GH and IGF-1 secretagogues [20]. Pediatric trials enrolled prepubertal children with idiopathic GHD as the principal population [3]. ### What not to mix with Sermorelin? Glucocorticoids and certain antithyroid agents have been reported to blunt the GH response to GHRH analogs in clinical pharmacology studies [18]. Concomitant somatostatin analogs are mechanistically antagonistic; concurrent recombinant GH is mechanistically redundant. ### Are there long-term side effects of Sermorelin? Long-duration trials are sparse; theoretical concerns include insulin resistance and IGF-1-mediated effects, though clinical signals in the available Sermorelin literature have been modest [9]. The broader GH-axis literature documents these concerns more thoroughly because the recombinant-GH and tesamorelin trial durations have been longer [13][20]. ### How long can you stay on Sermorelin? Published trial durations have ranged from single-dose pharmacodynamic studies to approximately 12 months of nightly dosing in pediatric GHD [3][4]. Adult research durations have typically been shorter — Khorram's 16-week cohort is representative of the longer adult published exposures [9]. ## Pharmacokinetics, Dosing, Administration ### What is Sermorelin half-life? Plasma half-life is short, on the order of 10-20 minutes — Frohman and colleagues reported approximately 11-12 minutes after IV or SC dosing in adults [5]. The GH-secretory pharmacodynamic effect persists 2-4 hours despite the short plasma half-life [12]. ### How is Sermorelin dosed in clinical studies? Pediatric idiopathic GHD trials used 30 mcg/kg subcutaneously at bedtime [3]. The pediatric diagnostic provocative test used 1 mcg/kg IV [6]. Adult research has used 10 mcg/kg subcutaneously nightly [9] or fixed-microgram regimens in the 0.2-0.5 mg range nightly. Framing throughout is studied-at, not prescriptive. ### Where is Sermorelin injected in studies? Subcutaneous injection, typically into the abdomen or thigh, administered at bedtime to align with the body's nocturnal GH pulse [3][9]. The intravenous route is reserved for diagnostic provocative testing at 1 mcg/kg [6]. ### Storage and Stability Lyophilized Sermorelin is stable refrigerated; once reconstituted, stability declines and refrigeration is standard per published handling guidance. The molecule is susceptible to N-terminal proteolytic degradation in plasma — the basis for the short plasma half-life [5]. ## Classification and Class Comparisons ### Is Sermorelin a Steroid? No. Sermorelin is a peptide (a short chain of amino acids), not a steroid. It acts on the GHRH receptor, a class B G-protein-coupled receptor [1][7], not on nuclear steroid receptors. The mechanism of action and the regulatory category are unrelated to anabolic-androgenic steroids. ### Is Sermorelin HGH? No. Sermorelin is a GHRH analog that stimulates the pituitary to release endogenous human growth hormone; it is not itself growth hormone. The upstream mechanism is the structural distinction from recombinant hGH replacement therapy, which supplies exogenous GH directly [20]. ### Is Sermorelin a GLP-1? No. Sermorelin is a GHRH analog acting on the pituitary GHRH receptor; GLP-1 agonists act on incretin pathways in the pancreas and elsewhere. The mechanisms, receptor families, and therapeutic categories are unrelated. ### How does Sermorelin compare to Ipamorelin? Sermorelin is a GHRH-receptor agonist; Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist [14]. The two stimulate GH release through distinct receptors on the same somatotroph population and are sometimes studied together for supra-additive effect [12][15]. ### How does Sermorelin compare to Tesamorelin? Both are GHRH analogs. Tesamorelin is a longer GHRH 1-44 analog stabilized with a trans-3-hexenoic acid modification, with substantially longer half-life and an FDA indication for HIV-associated lipodystrophy [13]. ### Can Tesamorelin and Sermorelin be combined? Both act on the same GHRH receptor, so combining them is mechanistically redundant rather than additive; the published literature does not support combined dosing within the GHRH-analog class. Combination across classes — GHRH analog with a GHRP — is the supra-additive pharmacology [12][15]. ## Regulatory and Demographic ### Is Sermorelin FDA-approved? Sermorelin acetate (under the historical FDA-approved branded product) was FDA-approved in 1997 for pediatric idiopathic GH deficiency at 30 mcg/kg/day subcutaneously, and was voluntarily discontinued from the US market in 2008 for commercial — not safety — reasons [17]. No FDA-approved branded Sermorelin product is currently marketed; compounded preparations exist under the FDA 503A/503B framework. ### Regulatory Status Sermorelin is a prescription substance in the US (no current FDA-approved branded product since 2008; compounded preparations exist) [17]. WADA prohibits Sermorelin and other GHRH analogs for competitive athletes under the S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics category. ### What does Sermorelin do for men in research contexts? Research in adult men has examined Sermorelin's effects on the somatotropic axis and IGF-1, with attention to age-related GH decline [9][10]. The Khorram 16-week cohort reported elevated nocturnal GH, elevated IGF-1, and lean body mass gain in the male subgroup [9]; Vittone reported restored youthful 24-h GH patterns in elderly men [10]. ### Can women use Sermorelin in research settings? Yes — pediatric GHD research enrolled both sexes [3][4], and adult studies have included female participants, though sex-disaggregated outcome data are sparser. Khorram's 16-week cohort enrolled nineteen men and women aged 55-71, with skin thickness increasing in both sexes [9]. ### Combining GHRH Analogs Both Sermorelin and tesamorelin act on the same GHRH receptor, so combining GHRH analogs is mechanistically redundant rather than additive. The supra-additive combination pharmacology is GHRH + GHRP (across receptor classes), not GHRH + GHRH (within receptor class) [12][15]. --- A bioluminescent reading room for the Sermorelin and GHRH (1-29) research record — pulsatile pharmacology read in the dark, cited line by line, and signed by no clinic and no vendor.